ProCE Banner Activity

AML Treatment Considerations for Oncology Nursing: On-Demand Webcast

Review this archived presentation by a nursing expert on the optimal management of patients with acute myeloid leukemia

Released: May 15, 2020

Expiration: May 14, 2021

No longer available for credit.

Share

Faculty

Elizabeth S. Kaled

Elizabeth S. Kaled, NP

Advanced Practice Nurse
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ayelet Nelson

Ayelet Nelson, ANP-BC

Outpatient Leukemia Nurse Practitioner
Division of Hematology/Oncology
Weill Cornell Medicine
New York, New York

Provided by

This activity is jointly provided by Global Education Group and MCM Education, in partnership with Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by an educational grant from

Jazz Pharmaceuticals Inc

Target Audience

The proposed learning activities are intended for oncology nurses, nurse practitioners, and other healthcare providers who manage and care for patients with AML, including nursing professionals affiliated with community and academic hospitals, oncology practices, or healthcare systems.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the phases of AML therapy (including treating leukostasis, and induction/consolidation therapy)
  • Outline individualized management plans for AML based on disease, patient, and agent characteristics
  • Identify recommendations for cytogenetic and molecular biomarkers that are used to select therapy in AML
  • Review newer approved and investigational targeted agents used along with chemotherapy for improved outcomes
  • Identify strategies for addressing quality-of-life concerns, supportive care needs for patients with AML
  • Discuss the management of treatment-related adverse events for patients with AML

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Elizabeth S. Kaled, NP

Advanced Practice Nurse
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elizabeth S. Kaled, NP, has no relevant conflicts of interest to report.

Ayelet Nelson, ANP-BC

Outpatient Leukemia Nurse Practitioner
Division of Hematology/Oncology
Weill Cornell Medicine
New York, New York

Ayelet Nelson, ANP-BC, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 15, 2020, through May 14, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this continuing education activity is to enhance knowledge and clinical competency among oncology nurses in the nursing care of patients with AML.